Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

Todd Neale

December 26, 2025

News Daily News

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

Caitlin E. Cox

August 15, 2019

News Daily News

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

Yael L. Maxwell

June 18, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

L.A. McKeown

February 20, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Conference News ISET 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

Caitlin E. Cox

February 07, 2017

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

L.A. McKeown

November 07, 2016

News Industry News

CARDIONOVUM Announces Enrollment Completion of RAPID Trial

June 06, 2016

News Industry News

CARDIONOVUM Announces Enrollment of First Patient in MAGNIFICENT Trial

April 07, 2016

News Industry News

Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial

October 27, 2015

News Industry News

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

October 14, 2015

News Daily News

STROLL at 3 Years: Nitinol Stent Demonstrates Sustained Patency, QoL in SFA Patients

L.A. McKeown

January 20, 2014

Advertisement

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

PET May Be Able to Pinpoint PAD Patients at Risk of Restenosis

FDA Class I Recall for PTA Catheters Due to Unexpected Balloon Bursting

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

‘Inadvertent Reversal’ of Late Mortality Data Flips Advantage From Paclitaxel Zilver PTX Stent in PAD to PTA

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

CARDIONOVUM Announces Enrollment Completion of RAPID Trial

CARDIONOVUM Announces Enrollment of First Patient in MAGNIFICENT Trial

Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial

Drug-Coated Balloon Shown To Be Superior To Conventional Angioplasty In Treating Superficial Femoral Artery Disease After Two Years

STROLL at 3 Years: Nitinol Stent Demonstrates Sustained Patency, QoL in SFA Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content